Hiroyuki Izutsu
6PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Dec 17, 2021
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato
|Aug 25, 2021
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.Yoshiya Tanaka, Tsutomu Takeuchi, Hiroyuki Izutsu
|Oct 14, 2020
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.Tsutomu Takeuchi, Yoshiya Tanaka, Mitsuhiro Rokuda
|Apr 30, 2020
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.Yoshiya Tanaka, Hiroyuki Izutsu
|Jul 28, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka
|Jul 28, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka
Pageof 1
